Tarsilla Spezialli Cardoso

Tarsilla Spezialli Cardoso

Auto-generated profile, based on publicly available information

Tarsilla Spezialli Cardoso

Universidade Federal de Minas Gerais, Belo Horizonte, Brasil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2018 in AIDS Care
Verified
Journal Article
Closed access
CACelline Almeida
Celline Almeida
EMErica E. M. Moodie
Erica E. M. Moodie
TCTarsilla Spezialli Cardoso
Tarsilla Spezialli Cardoso
ENElizabeth Do Nascimento
Elizabeth Do Nascimento
MCMaria Das Gracas Braga Ceccato
Maria Das Gracas Braga Ceccato
A critical feature of an adherence assessment tool is its ability to predict virologic failure in people living with HIV (PLHIV). We, therefore, aimed to compare the predictive performance of commonly used adherence measures. We systematically searched MEDLINE, Embase and LILACS up to February 2018, to identify relevant observational studies comparing the effects of any two of the following adherence measurements on virologic outcomes: electronic monitoring, pill count, pharmacy refill, self-report and physician assessment. We analyzed data by pairwise meta-analyzes with a random-effects model. The proportion of virologic failures among non-adherent participants in each adherence measure was used to calculate the odds ratio (OR), with 95% Confidence Intervals (95%CI). Heterogeneity was assessed, with potential causes identified by sensitivity and subgroup analysis. We included 38 studies with individual patient data for 18,010 patients. All possible comparisons between pairs of the five adherence measures were considered and a total of nine comparison groups could be established. Meta-analysis suggested that self-report was a better predictor of virologic failure than pill count when the recall period was within one week (OR: 2.35, 95%CI: 1.07–5.18, p = 0.03). Physician assessment had higher odds of predicting virologic failure than did either self-report (OR: 2.63, 95%CI: 1.37–5.26, p < 0.01) or pharmacy refill (OR: 3.57, 95%CI: 1.69–7.14, p < 0.001). There was no difference in the predictive performance between any of the other measures that we were able to compare (p > 0.05). The combination of multiple measures did not increase the predictive value when compared to any of the measures alone. Low-cost and simple adherence measures such as self-report predict virologic failure better than or equally well as objective measures. Our results suggest that there is no need to use expensive or time-consuming adherence measures when the objective is to identify PLHIV at risk of treatment failure.

1 January 2019 in Cadernos de Saude Publica
Verified
Journal Article
Open access
PDF file
TCTarsilla Spezialli Cardoso
Tarsilla Spezialli Cardoso
JCJuliana Costa
Juliana Costa
EREdna Afonso Reis
Edna Afonso Reis
MSMicheline Rosa Silveira
Micheline Rosa Silveira
PBPalmira de Fátima Bonolo
Palmira de Fátima Bonolo
MCMaria Das Gracas Braga Ceccato
Maria Das Gracas Braga Ceccato
We evaluated adherence to highly active antiretroviral therapy (HAART) and its associated factors according to the type of regimen in patients initiating treatment in Belo Horizonte, Minas Gerais State, Brazil. We measured adherence using the eight items Morisky Therapeutic Adhesion Scale (MMAS-8) and compared the use of “backbone” tenofovir/lamivudine plus efavirenz one tablet once-daily (STR) or dolutegravir in multi-tablet once-daily (MTR-DTG), or other multi-tablet regimens (MTR-other). We conducted a multivariate logistic regression analysis to address factors associated with adherence. A total of 393 patients were included, 254 used STR, 106 MTR-DTG, and 33 MTR-other. The overall adhesion rate was 44.8% (95%CI: 39.4; 50.1), 50% for MTR-DTG, 43.3% for STR and 39.4% for MTR-other. Multivariate analysis showed a higher chance of adherence among patients using MTR-DTG, those who received and understood counseling about their treatment and with a higher quality of life. Prior use of illicit drugs in the lifetime was associated with poorer adherence. Overall adherence was low, highlighting the need for strategies focusing on counseling about medicines and substance use. Pill burden was not an issue for patients using MTR-DTG once-daily, who achieved better results.